Guro Lind's group
Epigenetics
We focus our research on the cancer epigenome and DNA methylation in particular. By integrating large-scale analyses with detailed candidate gene characterization we aim at identifying DNA methylation biomarkers with clinical impact.
The group is member of "CoE - Centre for Cancer Biomedicine".
 | |
| RESEARCH THEMES |
Identification of novel epigenetic biomarkers for early detection of gastrointestinal cancer
Identification and characterization of epigenetic master keys in cancer development
Group contact information:
Department of Cancer Prevention, Institute for Cancer Research
Oslo University Hospital HE - Norwegian Radium Hospital
Mail address: P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway
Street address: Norwegian Radium Hospital, Montebello
Phone: +47 2278 1737
Guro.Elisabeth.Lind@rr-research.no
Print this page [2206 visits]Latest publications
Guro E. Lind
Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes
Breast Cancer Res Treat, 138 (1), 37-45
PubMed 23329352
A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors
Clin Transl Gastroenterol, 3, e27
PubMed 23324654
MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer
Neoplasia, 14 (9), 868-79
PubMed 23019418
More publications
